Abstract: The present invention provides methods for inhibiting smooth muscle cell proliferation, particularly smooth muscle cells present in blood vessel walls. A compound capable of inhibiting blood factor Xa is administered to the smooth muscle cells in an amount effective to inhibit proliferation of the cells. The compound capable of inhibiting blood factor Xa is preferably antistasin or tick anticoagulant peptide (TAP). In other aspects the present invention provides methods for treating atherosclerotic lesions and atherosclerosis, and methods of treating narrowing of the lumen of a blood vessel wherein the narrowing is caused at least in part by hyperplasia of smooth muscle cells in the wall of the blood vessel.

Abstract: Novel tumor cell growth inhibitor is a protein which can be obtained from the culture supernatant of 3T3 cell-derived cell line and which has the following properties:(a) molecular weight 3,700.+-.370 daltons when measured by SDS polyacrylamide gel electrophoresis under reducing and non-reducing conditions;(b) column propertythe inhibitor is not substantially adsorbed onto an anionic exchange resin column at pH of about 7.4 but is substantially adsorbed onto a cationic exchange resin column at pH of about 5.0The inhibitor has an inhibitory activity on human promyelogenic leukemia cells and human uterocervical tumor-derived cells and is useful for the treatment of leaukemia or uterus tumor.

Abstract: Insulin preparations containing nicotinamide or nicotinic acid or a salt thereof shown interesting pharmacological properties.

Abstract: A pure Factor I protein essentially free of infectious virus. Factor B and C3. The protein is derived from plasma and pasteurized by heating to a temperature of 50.degree. to 65.degree. C. for 0.5 to 100 hours in the presence of one or more stabilizers for Factor 1. Preparations containing the protein are useful in the treatment of Factor I deficiency and autoimmune diseases.

Abstract: Disclosed is a method for the regeneration of tissue, the treatment of external wounds and the treatment of periodontal disease comprising applying to the affected tissue an effective amount of a composition comprised of platelet-derived growth factor (PDGF) and an anti-inflammatory compound. The presence of the anti-inflammatory compound potentiates the activity of PDGF in stimulating cell growth, thereby enhancing tissue regeneration and/or wound healing.

Abstract: A method for treatment of inflammation, comprising the step of administering to a patient in need thereof an effective, inflammation-inhibiting amount of a composition comprising IL-6, or IL-6 and TGF.beta. together in a weight ratio of from about 5:95 to 95:5, preferably from about 20:80 to 80:20. Also disclosed is a composition for treatment of inflammation, comprising as active ingredients IL-6 and TGF.beta. in a weight ratio of from about 5:95 to about 95:5, optionally comprising a carrier in combination with the active ingredients, and a method of reducing migration of neutrophils into tissue of an animal which has received an inflammatory stimulus, comprising the step of administering to the tissue an effective neutrophil-migration-inhibiting amount of a composition as defined above.

Abstract: A method of retarding vascular leakage caused by tissue injury comprises administering a neurotensin or a neurotensin analog (SEQ ID NO: 1) at dosages sufficient to prevent or retard injury induced vascular leakage following injury or before deliberate injury.

Abstract: The present invention relates to fluorochemical blood substitutes used for preserving mammalian tissue having lysophosphatidyl compounds in non-toxic concentrations. More specifically, the invention relates to aqueous fluorochemical emulsions of a fluorochemical and an emulsifier useful as oxygen delivery agents and methods of preserving tissue in investigational and clinical settings, particularly those settings involving in in vivo transfusion, cardiac and other organ preservation, and in vitro organ perfusion.

Abstract: A process is described to purify collagen fibers while allowing the individual constituent molecules to retain their native configuration and 3-dimensional arrangement characteristic of the tissues from which they are derived. Collagenous tissues used as sources of purified collagen and for manufacturing bioprosthesis contain significant amounts of other substances (elastin, glycoproteins, polysaccharides, cell derived materials, etc.). This process becomes therefore useful to selectively preserve the collagen in its native conformation and to eliminate contaminants. The method described allows for enzymatic removal of all extraneous materials while preserving the native collagen molecules in their original fiber configuration.

Abstract: In the method for purifying factor VIII from cryoprecipitate, which is dissolved and then treated with alumina gel, the extract is diluted to a protein concentration not exceeding approximately 5 g/l and subjected to viral inactivation with solvent/detergent, the inactivated extract containing the solvent/detergent is then subjected to chromatography on a weak anion exchange column which is hydrophilic in nature and factor VIII is then eluted with a dissociating buffer.

Abstract: Secretory immunoglobulin A preparations substantially not containing virus are produced by a process wherein secretory immunoglobulin A which might be contaminated with viruses is (1) heated about 60.degree. C. for about 10 hours, or (2) subjected to the reaction with tri-n-butyl phosphate and a surfactant and the heating as mentioned above, as liquidized form in an aqueous medium, and then polymerized matters are precipitated from the resulting solution by adding polyethyleneglycol thereto.

Abstract: The present invention relates, in general, to oncoimmunins. In particular, the present invention relates to oncoimmunin-lymphoid factor and oncoimmunin-myeloid factor, pharmaceutical compositions of said factors, and methods of use of said factors.

Abstract: The therapy of patients with nephrotoxic or ischemic acute renal failure with epidermal growth factor and/or transforming growth factor-.alpha. is disclosed.

Abstract: A method for isolating the immunoglobulin compounds in the feces of animals and humans including the steps of placing said feces in a container with a buffer solution, homogenizing the feces in a phosphate buffer saline solution thereby forming a homogenized solution, separating the solids from the homogenized solution leaving a clear solution and chemically precipitating substantially all material contained in the clear solution with the exception of the immunoglobulin compounds through the use of protamine. The method produces a sufficient amount of immunoglobulin compounds for diagnostic and treatment purposes, if necessary. In particular, the production of IgAs has been quite useful for these purposes.

Abstract: Highly purified antihemophilic factor is produced by a process comprising a PEG precipitation step, a gel filtration step and a virus inactivation step. Al(OH).sub.3 adsorption and PEG precipitation carried out at room temperature allow processing to proceed directly to a gel filtration step.

Abstract: The present invention relates to a stable hemoglobin based composition having sufficiently low levels of methemoglobin to effectively function as an oxygen carrying solution upon administration to a patient made by the process comprising: a) adding an oxygenated or deoxygenated form of said blood substitute to an oxygen impermeable package, and b) storing said container at from between 5.degree. C. to 45.degree. C. for sufficient time to permit the autoreduction of methemoglobin. The stable hemoglobin based composition includes hemoglobin, modified hemoglobin and/or encapsulated hemoglobin. To effectively function as an oxygen carrying solution upon administration to a patient, the stable hemoglobin based solution cannot have greater than about 50% of said hemoglobin based solution in the methemoglobin form but, preferably no more than about 15%. The invention further relates to a method to store a stable oxygen carrying solution according to the above discussed process.

Abstract: Described is a preferred injectable, extended release formulation which includes a growth hormone or a growth hormone releasing factor in a carrier including a biocompatible hydrophobic vehicle and an amount of polyglycerol ester effective to extend release of the growth hormone or growth hormone releasing factor in an animal. Other preferred embodiments provide methods for making a composition for treating an animal with a growth hormone or growth hormone releasing factor, and methods for administering these substances to an animal.

Abstract: The invention is directed to a stroma-free tetrameric mammalian hemoglobin which is crosslinked with benzenepentacarboxylate, in which the crosslinking is carried out by a method comprising the step of activating at least two carboxylate groups of the benzenepentacarboxylate with an activating agent prior to reaction with the hemoglobin as well as methods for its production. Crosslinked stroma-free hemoglobin produced by methods of the present invention may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or as in a plasma expander.

Abstract: A method of sorting living cells based on DNA content. Mammalian sperm subpopulations enriched in X- or Y-sperm. X- and Y-enriched sperm-plasma-membrane vesicles. Substantially pure sex-associated membrane (SAM) proteins. Antibodies binding to X-or Y-SAM proteins, essentially free of antibodies binding to Y- or X-SAM proteins respectively, or to the H-Y antigen. Semen samples enriched for X- or Y-sperm. Methods for increasing the probability that offspring will be male or female comprising the step of allowing as penn from an enriched semen sample to fertilize an ovum. Methods for increasing the probability that offspring will be male or female comprising the step of immunizing a female with X- or Y-SAM proteins. Methods of decreasing fertility comprising the step of immunizing a female with both X- and Y-sperm. Methods of increasing the probability that mammalian offspring will carry a gene for a particular sex-chromosome linked trait.

Abstract: A polypeptide having the property of rendering a female Helicoverpa zea moth non-receptive to mating was isolated from the reproductive tract of the male moth. The peptide is transferred from the male to the female during mating and causes a depletion of the female sex pheromone thereby resulting in a decline in sexual attractiveness for at least 24 hours.The peptide is referred to as pheromonostatic peptide, or PSP. It is a basic peptide having 57 amino acid residues, a molecular weight of 6617 daltons and contains one pair of cysteine residues in a disulfide linkage.